Can you provide the average price target for PAVMED INC stock?
8 analysts have analysed PAVM and the average price target is 268.26 USD. This implies a price increase of 2803.25% is expected in the next year compared to the current price of 9.24.
PAVMED INC (PAVM) Forecast, Price Target & Analyst Ratings
NASDAQ:PAVM • US70387R5028
Current stock price
9.24 USD
-0.5 (-5.18%)
At close:
9 USD
-0.24 (-2.6%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PAVMED INC (PAVM).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.71
- Revenue Estimate
- 75.48K
Price Target Details & History
Consensus Price Target and Range
Mean target
$268.26
Upside
+ 2,803.25%
From current price of $9.24 to mean target of $268.26, Based on 8 analyst forecasts
Low
$16.16
Median
$268.26
High
$535.50
Price Target Revisions
1 Month
0.00%
3 Months
2,900.00%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for PAVM. The average price target is 268.26 USD. This implies a price increase of 2803.25% is expected in the next year compared to the current price of 9.24.
The average price target has been revised upward by 2900% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
PAVM was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about PAVM.
In the previous month the buy percentage consensus was at a similar level.
PAVM was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-09 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-12-10 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-10-06 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-06-06 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-04-21 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-12-09 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-09-10 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2023-08-18 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2023-01-20 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2023-01-18 | Lake Street | Maintains | Buy |
| 2022-08-17 | Lake Street | Maintains | Buy |
| 2021-03-30 | Cantor Fitzgerald | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.71
- Revenue Estimate
- 75.48K
- Revenue Q2Q
- 843.50%
- EPS Q2Q
- -107.00%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
-2,900.00%
Next Earnings Summary
PAVM is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -0.71 USD and the consensus revenue estimate is 75.48K USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates 2026 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.452M 545.26% | 2.995M 22.15% | 71K -97.63% | 499.8K 603.94% | 821.1K 64.29% | 243.37M 29,539.51% | 311.51M 28.00% | 389.44M 25.02% | |
| EBITDA YoY % growth | -65.863M 25.55% | -43.289M 34.27% | -21.701M 49.87% | -18.768M 13.52% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -68.795M 24.34% | -44.487M 35.33% | -21.806M 50.98% | -24.179M -10.88% | 21.318M 188.17% | 47.226M 121.53% | 79.152M 67.60% | 118.32M 49.48% | |
| Operating Margin | -2,805.67% | -1,485.38% | -30,712.68% | -4,837.65% | 2,596.27% | 19.41% | 25.41% | 30.38% | |
| EPS YoY % growth | -274.80 39.54% | -62.40 77.29% | -26.22 57.98% | -2.74 89.54% | -1.79 34.94% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.71 -107.00% | -0.68 96.92% | -0.67 92.26% | -0.67 87.80% |
| Revenue Q2Q % growth | 75.48K 843.50% | 99.96K 1,566.00% | 124.44K 2,388.80% | 199.92K 284.46% |
| EBITDA Q2Q % growth | -4.692M 13.16% | -4.692M -0.90% | -4.692M 1.37% | -4.692M 29.95% |
| EBIT Q2Q % growth | -6.103M -12.06% | -6.08M -28.95% | -6.148M -26.91% | -6.21M 8.72% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
1,289.18%
Revenue Next 5 Year
432.71%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
PAVMED INC / PAVM Forecast FAQ
When does PAVMED INC (PAVM) report earnings?
PAVMED INC (PAVM) will report earnings on 2026-05-12.
What are the consensus estimates for PAVM stock next earnings?
The consensus EPS estimate for the next earnings of PAVMED INC (PAVM) is -0.71 USD and the consensus revenue estimate is 75.48K USD.
What is the consensus rating for PAVM stock?
The consensus rating for PAVMED INC (PAVM) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.